Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
NEW YORK, July 31, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Ocular Therapeutix, Inc. ("Ocular Therapeutix") (NASDAQ:OCUL) securities between May 5, 2017 and July 6, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/ocular-therapeutix-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Ocular Therapeutix's management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could impact the approval of DEXTENZA by the FDA; and (3) as a result, defendants’ public statements were materially false and misleading.
If you suffered a loss in Ocular Therapeutix you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/ocular-therapeutix-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
